Johnson & Johnson’s coronavirus vaccine is approved by the U.S. Food and Drug Administration. It is now the third available vaccine in the United States as President Biden aims to protect as many people as possible by the summer end. It is the first one-dose vaccine in the U.S. and can also be quickly shipped and stores.
J&J would be a critical alternative for vaccinating hard-to-reach or skeptical Americans. On Saturday, FDA cleared that the vaccine is for the use of people 18 and over. Johnson & Johnson has 4 million shots ready on hand, according to Biden officials. The company said that it would provide 20 million doses by the end of March and 100 million total shots by the end of June.
President Biden, “There is light at the end of the tunnel, but we cannot let our guard down now or assume that victory is inevitable. We must continue to remain vigilant, act fast and aggressively, and look out for one another — that is how we are going to reach that light together.”
The efficacy rate of the vaccine is 66% against broad coronavirus infection. More importantly, it is good at curbing illness, death, and hospitalization says the pharmaceutical company. Gregory Poland, director of the Mayo Clinic’s vaccine research group, said, “We need vaccines that are effective and well-tolerated. And importantly, ones that are simple to deploy.”